Biodesix Inc. (BDSX) Misses Q1 EPS by 9c

Biodesix Inc. (NASDAQ: BDSX) reported Q1 EPS of ($0.26), $0.09 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $28.9 million versus the consensus estimate of $26.25 million.

“We were pleased with our strong operating and financial performance in the first quarter and believe we are off to a solid start in 2021,” said Scott Hutton, Chief Executive Officer. “We are encouraged by the trends in our core lung diagnostic testing. Additionally, Biodesix continues to innovate as demonstrated through our announcement of two new products and we are well-positioned for the future.”

For earnings history and earnings-related data on Biodesix Inc. (BDSX) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Park Dental Partners, Inc. (PARK) Tops Q2 EPS by 28c
• FGI Industries Ltd (FGI) Tops Q2 EPS by 59c